Ganglioside GM1

Generic Name: Ganglioside GM1

Drug Type: Small Molecule

Chemical Formula: C_₇₃H_₁₃₁N_₃O_₃₁

CAS Number: 116950-37-9

Unique Ingredient Identifier: 562413257Z

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer	2025/05/29	NCT06994507	Phase 3	Not yet recruiting	Qilu Pharmaceutical Co., Ltd.
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)	2023/03/02	NCT05751668	Phase 2	Recruiting	Alliance for Clinical Trials in Oncology
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction	2020/05/20	NCT04395339	Phase 3	Terminated	Sun Yat-sen University
Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer	2014/09/29	NCT02251977	Phase 3	Completed	Yuhong Li
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy	2014/03/21	NCT02093910	Phase 2	UNKNOWN	Sun Yat-sen University
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC	2013/12/31	NCT02024412	Phase 3	UNKNOWN	Tianjin Medical University Cancer Institute and Hospital
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer	2013/12/31	NCT02024438	Phase 3	UNKNOWN	Tianjin Medical University Cancer Institute and Hospital
Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study	2013/06/24	NCT01884987	N/A	UNKNOWN	Fudan University
GM1 Ganglioside Effects on Parkinson's Disease	2002/05/23	NCT00037830	Phase 2	Completed	Thomas Jefferson University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
Monosialotetrahexosylganglioside Sodium Injection	北京赛升药业股份有限公司	国药准字H20143201	化学药品	注射剂（小容量注射剂）	11/5/2024
Monosialotetrahexosylganglioside Sodium Injection	长春翔通药业有限公司	国药准字H20066833	化学药品	注射剂	8/10/2020
Monosialotetrahexosylganglioside Sodium Injection	北京赛升药业股份有限公司	国药准字H20143202	化学药品	注射剂（小容量注射剂）	11/5/2024
Monosialotetrahexosylganglioside Sodium Injection	北京四环制药有限公司	国药准字H20133300	化学药品	注射剂	11/11/2022
Monosialotetrahexosylganglioside Sodium Injection	哈尔滨医大药业股份有限公司	国药准字H20064601	化学药品	注射剂	4/7/2021
Monosialotetrahexosylganglioside Sodium Injection	山东齐鲁制药有限公司	国药准字H20056783	化学药品	注射剂	11/3/2021
Monosialotetrahexosylganglioside Sodium Injection	哈尔滨医大药业股份有限公司	国药准字H20083784	化学药品	注射剂	8/30/2023
Monosialotetrahexosylganglioside Sodium Injection	西南药业股份有限公司	国药准字H20093712	化学药品	注射剂	6/16/2019
Monosialotetrahexosylganglioside Sodium Injection	哈尔滨医大药业股份有限公司	国药准字H20083783	化学药品	注射剂	7/8/2020
Monosialotetrahexosylganglioside Sodium Injection	北京赛升药业股份有限公司	国药准字H20093980	化学药品	注射剂（小容量注射剂）	9/6/2024

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

No news found

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.